Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 427-432

  Emons, Günter ^a   Gorchev, Grigor ^b   Sehouli, Jalid ^c   Wimberger, Pauline ^d,j   Stähle, Anne ^e,k   Hanker, Lars ^f,l   Hilpert, Felix ^g   Sindermann, Herbert ^h   Gründker, Carsten ^a   Harter, Philipp ^i,m  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b University Hospital G Stranski   (Bulgaria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Department of Gynecology and Obstetrics   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h Aeterna Zentaris GmbH   (Germany)

ⁱ DR HORST SCHMIDT KLINIKEN   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k Universitätsklinikum Schleswig Holstein Campus Lübeck ^*  (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m KLINIKEN ESSEN MITTE   (Germany)

more..

Author keywords

LHRH receptor targeted; Ovarian cancer; Platinum refractory; Platinum resistant; Targeted chemotherapy

Indexed keywords

CA 125 ANTIGEN; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; GONADORELIN RECEPTOR; PLATINUM; ZOPTARELIN DOXORUBICIN;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOCYTOPENIA; HEADACHE; HUMAN; INJECTION SITE EDEMA; INJECTION SITE PAIN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PNUEMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT REDUCTION;

LHRH RECEPTOR TARGETED; OVARIAN CANCER; PLATINUM-REFRACTORY; PLATINUM-RESISTANT; TARGETED CHEMOTHERAPY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; RECEPTORS, LHRH; TAXOIDS; TREATMENT OUTCOME;

EID: 84901687669     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.576     Document Type: Article

References (25)

1. American Cancer Society: Cancer Facts and Figs. 2013 2013 American Cancer Society Inc. Atlanta, GA
2. ECO, European Cancer Observatory International Agency for Research on Cancer http://eu-cancer.iarc.fr [accessed on 25/03/2013]
3. T.A. Lawrie, A. Bryant, A. Cameron, E. Gray, and J. Morrison Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer Cochrane Database Syst Rev 7 2013 10.1002/14651858. CD006910.pub2 [Art. No.: CD006910]
4. N. Colombo, E. Kutarska, M. Dimopoulos, D.-S. Bae, I. Rzepka-Gorskar, and M. Bidzinski et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer J Clin Oncol 30 2012 3841 3847
5. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancer de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
6. L.C. Hanker, S. Loibl, N. Burchardi, J. Pfisterer, W. Meier, and E. Pujade-Lauraine et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy Ann Oncol 23 2012 2605 2612
7. J. Sehouli, D. Stengel, P. Harter, C. Kurzeder, T. Bogenrieder, and S. Markmann et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 29 2011 242 248
8. G. Halmos, A. Nagy, N. Lamharzi, and A.V. Schally Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers Cancer Lett 136 1999 129 136
9. A.M. Bajo, A.V. Schally, G. Halmos, and A. Nagy Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers Clin Cancer Res 9 2003 3742 3748
10. G. Emons, O. Ortmann, K.D. Schulz, and A.V. Schally Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells Trends Endocrinol Metab 8 1997 355 362
11. S. Westphalen, G. Kotulla, F. Kaiser, W. Krauss, G. Werning, and H.P. Elsässer et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines Int J Oncol 17 2000 1063 1069
12. G. Emons, H. Sindermann, J. Engel, A. Schally, and C. Gründker et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152 Neuroendocrinology 90 2009 15 18
13. C. Grundker, P. Volker, F. Griesinger, A. Ramaswamy, A. Nagy, and A.V. Schally et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice Am J Obstet Gynecol 187 2002 528 537
14. G. Emons, M. Kaufmann, G. Gorchev, V. Tsekova, C. Gründker, and A.R. Günthert et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors Gynecol Oncol 119 2010 457 461
15. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
16. Gynecologic Cancer Intergroup CA-125 definitions agreed by GCIG November 2005 http://www.gcig.igcs.org/CA125/respdef-nov2005.pdf 2005
17. C. Fost, F. Duwe, M. Hellriegel, S. Schweyer, G. Emons, and Carsten Gründker et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor Oncol Rep 25 2011 1481 1487
18. G.J. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, and T. Thigpen et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21 2011 419 423
19. T.T. Chen, and T.H. Ng Optimal flexible designs in phase II clinical trials Stat Med 17 1998 2301 2312
20. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
21. G. Emons, and J.J. Kavanagh Hormonal interactions in ovarian cancer Hematol Oncol Clin North Am 13 1999 145 161
22. C.F. Verschraegen, S. Westphalen, W. Hu, E. Loyer, A. Kudelka, and P. Völker et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer Gynecol Oncol 90 2003 552 559
23. C.L. Walters, R.C. Arend, D.K. Armstrong, R.W. Naumann, and R.D. Alvarez et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer Gynecol Oncol 131 2013 493 498
24. C.F. Verschraegen, S. Czok, C.Y. Muller, L. Boyd, S.J. Lee, and T. Rutledge et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer Ann Oncol 23 2012 3104 3110
25. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 Suppl. 18 2012 [abstr LBA 5002]